CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+6.25%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.86B
AUM Growth
+$2.86B
(-0.01%)
Cap. Flow
-$294M
Cap. Flow
% of AUM
-10.27%
Top 10 Holdings %
Top 10 Hldgs %
64.87%
Holding
43
New
5
Increased
6
Reduced
7
Closed
7
Top Buys
| 1 |
Biogen
BIIB
|
$86.3M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$57.2M |
| 3 |
Denali Therapeutics
DNLI
|
$30.8M |
| 4 |
Qiagen
QGEN
|
$25.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$21.8M |
Top Sells
| 1 |
Tenet Healthcare
THC
|
$194M |
| 2 |
Universal Health Services
UHS
|
$113M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$43.8M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$43M |
| 5 |
QuidelOrtho
QDEL
|
$29.5M |
Sector Composition
| 1 | Healthcare | 96.94% |
| 2 | Consumer Staples | 1.6% |
| 3 | Consumer Discretionary | 0.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $254M | 6.23% | 1,925,000 | – | – |
|
|
2
Universal Health Services
UHS
$11.6B
| $228M | 5.59% | 1,250,000 -620,000 | -33% | -$113M |
|
3
Baxter International
BAX
$12.7B
| $214M | 5.24% | 5,000,000 | – | – |
|
|
4
Tenet Healthcare
THC
$16.3B
| $200M | 4.89% | 1,900,000 -1,845,000 | -49% | -$194M |
|
5
Viatris
VTRS
$12.3B
| $194M | 4.76% | 16,250,000 -2,250,000 | -12% | -$26.9M |
|
|
WBA
6
DELISTED
Walgreens Boots Alliance
WBA
| $169M | 4.15% | 7,800,000 +800,000 | +11% | +$17.4M |
|
7
Myriad Genetics
MYGN
$593M
| $163M | 3.99% | 7,635,000 | – | – |
|
8
Medtronic
MDT
$119B
| $161M | 3.95% | 1,850,000 | – | – |
|
|
9
Jazz Pharmaceuticals
JAZZ
$7.75B
| $138M | 3.39% | 1,150,000 +475,000 | +70% | +$57.2M |
|
10
Globus Medical
GMED
$8.27B
| $134M | 3.29% | 2,500,000 +250,000 | +11% | +$13.4M |
|
11
PTC Therapeutics
PTCT
$3.92B
| $116M | 2.85% | 4,000,000 | – | – |
|
12
Select Medical
SEM
$1.61B
| $103M | 2.51% | 3,400,000 | – | – |
|
13
Brookdale Senior Living
BKD
$1.83B
| $102M | 2.51% | 15,500,000 | – | – |
|
14
GSK
GSK
$79.9B
| $93.2M | 2.29% | 2,175,000 | – | – |
|
|
15
Biogen
BIIB
$19.4B
| $86.3M | 2.11% | +400,000 | New | +$86.3M |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $75.7M | 1.86% | 585,000 -215,000 | -27% | -$27.8M |
|
17
ZimVie
ZIMV
$532M
| $53.6M | 1.31% | 3,250,000 | – | – |
|
|
18
Qiagen
QGEN
$10.1B
| $52M | 1.27% | 1,210,000 +595,000 | +97% | +$25.6M |
|
19
Perrigo
PRGO
$3.27B
| $48.9M | 1.2% | 1,520,000 -330,000 | -18% | -$10.6M |
|
20
Collegium Pharmaceutical
COLL
$1.22B
| $33.1M | 0.81% | 852,900 -197,100 | -19% | -$7.65M |
|
|
21
Denali Therapeutics
DNLI
$2.23B
| $30.8M | 0.75% | +1,500,000 | New | +$30.8M |
|
22
Herbalife
HLF
$1.01B
| $30.2M | 0.74% | 3,000,000 +1,000,000 | +50% | +$10.1M |
|
23
OraSure Technologies
OSUR
$242M
| $26.1M | 0.64% | 4,250,000 | – | – |
|
|
BKDT
24
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| $22.7M | 0.56% | 250,000 | – | – |
|
25
Replimune Group
REPL
$422M
| $22.5M | 0.55% | 2,750,000 +1,750,000 | +175% | +$14.3M |
|